🇺🇸 FDA
Patent

US 11529360

Natural combination hormone replacement formulations and therapies

granted A61KA61K31/565A61K31/57

Quick answer

US patent 11529360 (Natural combination hormone replacement formulations and therapies) held by Compass Therapeutics LLC expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Compass Therapeutics LLC
Grant date
Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/565, A61K31/57, A61K47/10, A61K47/14